

# K John Pasi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8805658/publications.pdf>

Version: 2024-02-01

37  
papers

4,252  
citations

516561

16  
h-index

345118

36  
g-index

40  
all docs

40  
docs citations

40  
times ranked

4300  
citing authors

#	ARTICLE	IF	CITATIONS
1	Adenovirus-Associated Virus Vector-Mediated Gene Transfer in Hemophilia B. <i>New England Journal of Medicine</i> , 2011, 365, 2357-2365.	13.9	1,606
2	AAV5-Factor VIII Gene Transfer in Severe Hemophilia A. <i>New England Journal of Medicine</i> , 2017, 377, 2519-2530.	13.9	529
3	Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 288-290.	13.9	418
4	Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. <i>Blood</i> , 2014, 123, 317-325.	0.6	403
5	Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A. <i>New England Journal of Medicine</i> , 2020, 382, 29-40.	13.9	316
6	Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B. <i>New England Journal of Medicine</i> , 2013, 369, 2313-2323.	13.9	307
7	Valoctocogene Roxaparovec Gene Therapy for Hemophilia A. <i>New England Journal of Medicine</i> , 2022, 386, 1013-1025.	13.9	157
8	Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-Results of the phase 1 inhibitor cohort. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1436-1446.	1.9	62
9	Persistence of haemostatic response following gene therapy with valoctocogene roxaparovec in severe haemophilia A. <i>Haemophilia</i> , 2021, 27, 947-956.	1.0	62
10	Clinical Considerations for Capsid Choice in the Development of Liver-Targeted AAV-Based Gene Transfer. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 15, 170-178.	1.8	55
11	Activity of transgene-produced B-domain-deleted factor VIII in human plasma following AAV5 gene therapy. <i>Blood</i> , 2020, 136, 2524-2534.	0.6	48
12	Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A. <i>Nature Medicine</i> , 2022, 28, 789-797.	15.2	48
13	Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study. <i>Haemophilia</i> , 2020, 26, 494-502.	1.0	44
14	Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome. <i>Blood</i> , 2020, 136, 1956-1967.	0.6	34
15	Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B. <i>Thrombosis and Haemostasis</i> , 2017, 117, 508-518.	1.8	31
16	Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the BAYOND extension study. <i>Haemophilia</i> , 2020, 26, e262-e271.	1.0	28
17	Towards a global multidisciplinary consensus framework on haemophilia gene therapy: Report of the 2nd World Federation of Haemophilia Gene Therapy Round Table. <i>Haemophilia</i> , 2020, 26, 443-449.	1.0	15
18	Evolution of haemophilia integrated care in the era of gene therapy: Treatment centres' readiness in United States and EU. <i>Haemophilia</i> , 2021, 27, 511-514.	1.0	13

#	ARTICLE	IF	CITATIONS
19	Recombinant factor VIII Fc for the treatment of haemophilia A. European Journal of Haematology, 2021, 106, 745-761.	1.1	11
20	Propelling Healthcare with Advanced Therapy Medicinal Products: A Policy Discussion. Biomedicine Hub, 2020, 5, 1-23.	0.4	11
21	First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies. Blood, 2020, 136, LBA-6-LBA-6.	0.6	11
22	Predicting FVIII Activity in Patients Who Use Recombinant FVIII Fc Fusion Protein for Prophylaxis and Treatment of Bleeding Episodes. Blood, 2014, 124, 1522-1522.	0.6	5
23	First-in-Human Phase 1/2 Clinical Trial of SIG-001, an Innovative Shielded Cell Therapy Platform, for Hemophilia B. Blood, 2020, 136, 8-8.	0.6	4
24	Adeno-Associated Viral Vector Mediated Gene Transfer for Hemophilia B. Blood, 2011, 118, 5-5.	0.6	4
25	Safety, Efficacy, and Pharmacokinetics of Recombinant Factor VIII Fc Fusion Protein (rFVIII Fc) in Previously-Treated Children with Severe Hemophilia a (Kids-ALONG). Blood, 2014, 124, 1494-1494.	0.6	4
26	The impact of factor infusion frequency on health-related quality of life in people with haemophilia. The Journal of Haemophilia Practice, 2020, 7, 102-109.	0.2	4
27	Gene therapy trials for haemophilia: a step closer to a cure?. Expert Review of Precision Medicine and Drug Development, 2019, 4, 259-262.	0.4	3
28	Long-Term Durability, Safety and Efficacy of Fitusiran Prophylaxis in People with Hemophilia a or B, with or without Inhibitors - Results from the Phase II Study. Blood, 2020, 136, 3-4.	0.6	3
29	Longitudinal Assessment of Thrombin Generation in Patients with Hemophilia Receiving Fitusiran Prophylaxis: Phase II Study Results. Blood, 2020, 136, 36-37.	0.6	3
30	Examination and Validation of a Patient-Centric Joint Metric: "Problem Joint"; Empirical Evidence from the CHESS US Dataset. Blood, 2020, 136, 25-26.	0.6	2
31	Improvement in pain-related quality of life in patients with hemophilia A treated with rFVIII Fc individualized prophylaxis: post hoc analysis from the A-LONG study. Therapeutic Advances in Hematology, 2022, 13, 204062072210794.	1.1	2
32	Efficacy of Nuwiq® (Simoctocog Alfa) in Patients with Hemophilia A Who Changed and Adhered to a Pharmacokinetic-Guided Prophylaxis Regimen in the NuPreviq Study. Clinical Medicine Insights Blood Disorders, 2021, 14, 263485352199151.	0.3	1
33	A Two Centre Experience Of Use Of a Dual Virally Inactivated FVIII/VWF Product (Wilate®) In Patients With Von Willebrand Disease. Blood, 2013, 122, 1112-1112.	0.6	1
34	The Bleeding Tendency In Relation To Predicted FVIII Activity Levels In Severe Hemophilia A Patients Treated With Recombinant Factor VIII Fc Fusion Protein. Blood, 2013, 122, 3590-3590.	0.6	1
35	Personalized Prophylaxis with Human-C1 Recombinant FVIII in HA Patients. Blood, 2015, 126, 547-547.	0.6	1
36	Pharmacokinetics, Safety, and Efficacy Of Long-Lasting Recombinant Factor IX Fc Fusion Protein (rFIX Fc) In Adolescent Subjects With Hemophilia B: A Subgroup Analysis Of The B-LONG Study. Blood, 2013, 122, 2350-2350.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Predicting FIX Activity in Prophylaxis Patients Using Recombinant FIX Fc Fusion Protein for Treatment of Bleeding Episodes. Blood, 2014, 124, 2842-2842.	0.6	0